You are here

Point-of-care immunoassay panel for cardiotonic steroids

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HD079238-01A1
Agency Tracking Number: R43HD079238
Amount: $224,999.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NICHD
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1230 BORDEAUX DRIVE
SUNNYVALE, CA 94089-1202
United States
DUNS: 556962439
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JAMES LARRICK
 (415) 264-6311
 jwlarrick@gmail.com
Business Contact
 ERIC HOANG
Phone: (408) 747-5201
Email: ops@pano.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Preeclampsia (PE) is a serious complication of pregnancy manifested by high blood pressure, proteinuria, and edema, sometimes with encephalopathy, seizures, and hepatic failure. PE complicates from 5 to 10% of pregnancies, and is a major cause of maternal a fetal morbidity and mortality worldwide. Elevation in the circulating level of an endogenous digoxin-like factor (EDLF), an unknown substance that cross reacts with anti-digoxin antibodies and inhibits the NA+/K+ ATPase (NKA) was first noted in the 1980s. An extensive literature supports the hypothesis that increased levels of EDLF may be causative factor in the pathogenesis of hypertension. Recently, marinobufagenin (MBG), an endogenous cardiotonic steroid (CTS), has been identified as the EDLF. Plasma MBG is elevated over five-fold in pregnancies complicated by PE, suggesting a role pathophysiological role. Digibind, an anti-digoxin antiserum that cross-reacts MBG, provided significant in improvement in renal functi

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government